Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect of Supplementation on Insulin Requirements
This study has been completed.
Information provided by (Responsible Party):
Peter Gerrits, MD, William Beaumont Hospitals
First received: December 9, 2009
Last updated: March 3, 2017
Last verified: December 2016
Our objective is to demonstrate that providing supplemental vitamin D to children with new onset DM will significantly decrease the levels of HbA1c and insulin requirement by the following methods.
- Identify how often vitamin D levels are low in patients with new onset Type 1 diabetes mellitus (DM).
- Record the hemoglobin A1c (HbA1c) level (which reflects the average blood sugar level over the past few months) and document insulin requirements before and after vitamin supplementation is given.
Hypothesis: Maintaining vitamin D levels >30 ng/ml will decrease HbA1c and insulin requirements.
Type 1 Diabetes Mellitus
Drug: Vitamin D
Intervention Model: Parallel Assignment
Intervention Model Description:
Patients with clinically significantly low Vitamin D levels (<30 ng/mL) were supplemented with Vitamin D and compared to patients with normal vitamin D levels (50-80 nG/mL).Masking: None (Open Label)
Primary Purpose: Health Services Research
||Prevalence of Vitamin D Deficiency in Type 1 Diabetes Mellitus and Effect on Insulin Requirements After Supplementation With Vitamin D-A Pilot Study
Primary Outcome Measures:
Secondary Outcome Measures:
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||June 2012 (Final data collection date for primary outcome measure)
Experimental: Required Vitamin D
Those children whose Vitamin D level was low (<30 ng/mL) are given Vitamin D supplementation
Drug: Vitamin D
2000iu once a day
Other Name: cholecalciferol
No Intervention: Normal Vitamin D
Those children whose Vitamin D level was normal (50-80 ng/mL) did not receive Vitamin D supplementation
New onset type 1 DM patients who present at William Beaumont Hospital, Royal Oak or to the Pediatric Endocrine Clinic will be approached about the study at their presentation and time will be given for the patient and family to discuss and ask questions regarding the study. Patients will then be enrolled following informed consent. Glucose levels and insulin requirements will be monitored continuously from the faxed weekly logbooks from the point of diagnosis for 3 months (as standard practice for all newly diagnosed diabetic patients in our clinic). At the baseline visit a Vitamin D level will be drawn and frozen for 3 months prior to processing. .After 3 months vitamin D, calcium, alkaline phosphatase, phosphorus and other standard of care lab draws will be done. Approximately an additional 3 tsp of blood will be taken. All female subjects of child bearing potential will have a pregnancy test done. EMLA cream to anesthetize the area will be used prior to blood draw. A vitamin D level of <30 ng/ml is considered insufficient and the patient will then be given vitamin D supplement. The vitamin D level, calcium, alkaline phosphatase and phosphorus will be rechecked at 6 months (additional 3 tsp of blood) . Glucose levels and insulin requirements will be monitored continuously from the faxed weekly logbooks again for another 3 months.
|Ages Eligible for Study:
||1 Year to 18 Years (Child, Adult)
|Sexes Eligible for Study:
|Accepts Healthy Volunteers:
- Newly diagnosed type I DM.
- Age <18 years
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01029392
|Royal Oak, Michigan, United States, 48073 |
William Beaumont Hospitals
||Peter Gerrits, MD
||William Beaumont Hospitals
||Peter Gerrits, MD, Principal Investigator, William Beaumont Hospitals
History of Changes
|Other Study ID Numbers:
|Study First Received:
||December 9, 2009
|Results First Received:
||December 13, 2016
||March 3, 2017
|Individual Participant Data (IPD) Sharing Statement:
|Plan to Share IPD:
||No data sharing.
Keywords provided by Peter Gerrits, MD, William Beaumont Hospitals:
Newly Diagnosis Type I Diabetes Mellitus
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on September 21, 2017
Diabetes Mellitus, Type 1
Vitamin D Deficiency
Glucose Metabolism Disorders
Endocrine System Diseases
Immune System Diseases
Physiological Effects of Drugs
Bone Density Conservation Agents